Abstract
Purpose
To determine eye drop type and usage frequency and investigate risk factors for no eye drop use in individuals with symptomatic dry eye (DE) in Japan.
Study design
Crowdsourced observational study.
Methods
This study was conducted using the DryEyeRhythm smartphone application between November 2016 and September 2019. Data collected included the type and frequency of eye drop use, demographics, medical history, lifestyle, and self-reported symptoms. Symptomatic DE was defined as an Ocular Surface Disease Index total score of ≥ 13. Risk factors for no eye drop use were identified using multivariate logistic regression analyses.
Results
Among 2619 individuals with symptomatic DE, 1876 did not use eye drops. The most common eye drop type was artificial tears (53.4%), followed by hyaluronic acid 0.1% (33.1%) and diquafosol sodium 3% (18.7%). Risk factors (odds ratio [95% confidence interval]) for no eye drop use were age (0.97 [0.97–0.98]), body mass index (1.04 [1.01–1.07]), brain disease (0.38 [0.15–0.98]), collagen disease (0.30 [0.13–0.68]), mental illness other than depression and schizophrenia (0.65 [0.45–0.93]), cataract surgery (0.12 [0.02–0.59]), ophthalmic surgery other than cataract and laser-assisted in situ keratomileusis (0.55 [0.34–0.88]), current (0.47 [0.38–0.57]) or past (0.58 [0.43–0.77]) contact lens use, >8 h screen exposure time (1.38 [1.05–1.81]), <6 h (1.24 [1.01–1.52]) and >9 h (1.34 [1.04–1.72]) sleep time, and water intake (0.97 [0.94–0.98]).
Conclusion
Many participants with symptomatic DE did not use optimized eye drop treatment and identified risk factors for no eye drop use. The DryEyeRhythm application may help improve DE treatment.
Similar content being viewed by others
References
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15:276–83.
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15:334–65. https://doi.org/10.1016/j.jtos.2017.05.003.
Hikichi T, Yoshida A, Fukui Y, Hamano T, Ri M, Araki K, et al. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408–11.
Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea. 1999;18:408–11.
Uchino M, Nishiwaki Y, Michikawa T, Shirakawa K, Kuwahara E, Yamada M, et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology. 2011;118:2361–7.
Uchino M, Yokoi N, Uchino Y, Dogru M, Kawashima M, Komuro A, et al. Prevalence of dry eye disease and its risk factors in visual display terminal users: the Osaka study. Am J Ophthalmol. 2013;156:759–66.
Inomata T, Shiang T, Iwagami M, Sakemi F, Fujimoto K, Okumura Y, et al. Changes in distribution of dry eye disease by the new 2016 diagnostic criteria from the Asia Dry Eye Society. Sci Rep. 2018;8:1918.
Courtin R, Pereira B, Naughton G, Chamoux A, Chiambaretta F, Lanhers C, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016;6:e009675.
Inomata T, Iwagami M, Nakamura M, Shiang T, Yoshimura Y, Fujimoto K, et al. Characteristics and risk factors associated with diagnosed and undiagnosed symptomatic dry eye using a smartphone application. JAMA Ophthalmol. 2019;138:58–68.
Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013;1:51–7.
Yamada M, Mizuno Y, Shigeyasu C. Impact of dry eye on work productivity. Clinicoecon Outcomes Res. 2012;4:307–12.
Yokoi N, Georgiev GA. Tear film-oriented diagnosis and tear film-oriented therapy for dry eye based on tear film dynamics. Investig Ophthalmol Vis Sci. 2018;59:13–22.
Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575–628.
Poon KH, Yeo S, Tong L. Lost to follow-up for appointments in a dedicated dry eye clinic. Patient Prefer Adherence. 2014;8:1409–18.
Narayan V. Pharmaceutical ophthalmic market perspectivees in India and emerging trends. CLEVER. 2018;1:35–7.
Kawashima M, Yamada M, Suwaki K, Shigeyasu C, Uchino M, Hiratsuka Y, et al. A clinic-based survey of clinical characteristics and practice pattern of dry eye in Japan. Adv Ther. 2017;34:732–43.
Uchino M, Yokoi N, Kawashima M, Ryutaro Y, Uchino Y, Tsubota K. Treatment trends in dry eye disease and factors associated with ophthalmic follow-up discontinuation in Japan. J Clin Med. 2019;8:1120.
Mizuno Y, Yamada M, Shigeyasu C. Annual direct cost of dry eye in Japan. Clin Ophthalmol. 2012;6:755–60.
World Health Organization. mHealth: new horizons for health through mobile technologies: second global survey on eHealth; 2011. https://www.who.int/goe/publications/goe_mhealth_web.pdf. Accessed 6 Dec 2019.
Byambasuren O, Sanders S, Beller E, Glasziou P. Prescribable mHealth apps identified from an overview of systematic reviews. NPJ Digit Med. 2018;1:12.
Inomata T, Nakamura M, Iwagami M, Shiang T, Yoshimura Y, Fujimoto K, et al. Risk factors for severe dry eye disease: crowdsourced research using DryEyeRhythm. Ophthalmology. 2019;126:766–8.
Inomata T, Iwagami M, Nakamura M, Shiang T, Fujimoto K, Okumura Y, et al. Association between dry eye and depressive symptoms: large-scale crowdsourced research using the DryEyeRhythm iPhone application. Ocul Surf. 2020;18:312–9.
Pereira AM, Jácome C, Almeida R, Fonseca JA. How the smartphone is changing allergy diagnostics. Curr Allergy Asthma Rep. 2018;18:69.
World Medical Association. Worl Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.
Midorikawa-Inomata A, Inomata T, Nojiri S, Nakamura M, Iwagami M, Fujimoto K, et al. Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease. BMJ Open. 2019;9:e033940.
Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry. 1965;12:63–70.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.
Inomata T, Nakamura M, Iwagami M, Midorikawa-Inomata A, Okumura Y, Fujimoto K, et al. Comparing the Japanese version of the ocular surface disease index and dry eye-related quality-of-life score for dry eye symptom assessment. Diagnostics (Basel). 2020;10:203.
Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128:94–101.
Kim KW, Han SB, Han ER, Woo SJ, Lee JJ, Yoon JC, et al. Association between depression and dry eye disease in an elderly population. Investig Ophthalmol Vis Sci. 2011;52:7954–8.
Yazdani C, McLaughlin T, Smeeding JE, Walt J. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672–82.
Watanabe H. Medical treatment for dry eye in Japan. Investig Ophthalmol Vis Sci. 2018;59:des116–20.
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology Report. Ocul Surf. 2017;15:539–74.
Inomata T, Iwagami M, Hiratsuka Y, Fujimoto K, Okumura Y, Shiang T, et al. Maximum blink interval is associated with tear film breakup time: a new simple, screening test for dry eye disease. Sci Rep. 2018;8:13443.
Fujimoto K, Inomata T, Okumura Y, Iwata N, Fujio K, Eguchi A, et al. Comparison of corneal thickness in patients with dry eye disease using the Pentacam rotating Scheimpflug camera and anterior segment optical coherence tomography. PLoS ONE. 2020;15:e0228567.
Inomata T, Sung J, Nakamura M, Fujisawa K, Muto K, Ebihara N, et al. New medical big data for P4 medicine on allergic conjunctivitis. Allergol Int. 2020;69:510–8.
Jardine J, Fisher J, Carrick B. Apple’s ResearchKit: smart data collection for the smartphone era? J R Soc Med. 2015;108:294–6.
Heidari M, Noorizadeh F, Wu K, Inomata T, Mashaghi A. Dry eye disease: emerging approaches to disease analysis and therapy. J Clin Med. 2020;8:751–60.
Acknowledgements
Special thanks to OHAKO, Inc. (Tokyo, Japan) for developing the DryEyeRhythm application and Shiang T, Yoshimura Y, Hirastuka Y, Uchino M, and Tsubota K for initiating the development of the application.
Funding
This study was supported by SEED Co., Ltd (Tokyo, Japan), Alcon Japan, Ltd, Tokyo Japan; Rohto Pharmaceutical Co., Ltd, Osaka, Japan; HOYA Corporation, Tokyo, Japan; and WAKAMOTO Co., Ltd, Tokyo, Japan. The sponsors had no role in the design or conduct of this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The DryEyeRhythm application was developed by OHAKO, Inc. (Tokyo, Japan), using Apple’s ResearchKit (Cupertino, CA, USA). The authors do not have any conflict of interest relevant to this study.
A. Eguchi, None; T. Inomata, Grant (Johnson & Johnson, Kowa, Novartis, Santen, SEED, HOGY), Consultant fee (Santen); M. Nakamura, None; K. Nagino, None; M. Iwagami, None; J. Sung, None; A. Midorikawa-Inomata, None; Y. Okumura, None; K. Fujio, None; K. Fujimoto, None; M. Miura, None; Y. Akasaki, None; H. Shokirova, None; K. Hirosawa, None; M. Kuwahara, None; J. Zhu, None; R. Dana, Financial support (Dompé, Aldeyra, Kala); A. Murakami, Grant (Eisai, Kowa, Novartis, HOYA, ROHTO, Alcon, AMO, Otsuka, SEED, Senju, Pfizer, Santen), Financial support (Johnson & Johnson, Kowa, Lion, Alcon, Santen, Otsuka); H. Kobayashi, None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Corresponding Author: Takenori Inomata
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 (MP4 3841 KB)
About this article
Cite this article
Eguchi, A., Inomata, T., Nakamura, M. et al. Heterogeneity of eye drop use among symptomatic dry eye individuals in Japan: large-scale crowdsourced research using DryEyeRhythm application. Jpn J Ophthalmol 65, 271–281 (2021). https://doi.org/10.1007/s10384-020-00798-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-020-00798-1